FDA Clears First U.S. Ibogaine-Derivative Trial for Alcohol Use Disorder

DemeRx announced in late April 2026 that the FDA has accepted its Investigational New Drug (IND) application for DMX-1001, an oral noribogaine formulation being developed as a treatment for alcohol use disorder. This is the first time the FDA has allowed a clinical study of an ibogaine-derived compound in the United States.

What Noribogaine Is

Ibogaine is a naturally occurring psychoactive alkaloid from the African plant Tabernanthe iboga. Noribogaine is ibogaine primary metabolite. Unlike ibogaine, which clears the body in 4-7 hours, noribogaine remains active for 24-48+ hours or longer, driving neuroplastic changes that may help repair circuits damaged by chronic substance use. DemeRx designed DMX-1001 specifically to reduce the cardiac risks associated with the parent compound.

Where the Research Stands

DemeRx recently completed a multiple ascending dose trial in healthy volunteers with acceptable safety and tolerability. The FDA IND acceptance green-lights Phase 2 trials in people with alcohol use disorder. Alcohol use disorder affects more than 29 million Americans and is a leading cause of preventable death. Fewer than 10% of people with AUD receive medication-assisted treatment.

Why This Matters for People in Recovery

The FDA willingness to clear ibogaine-derivative research in the U.S. reflects a broader shift in how regulators are approaching psychedelic-adjacent compounds with addiction medicine potential. Find current alcohol use disorder treatment options near you.